Swift Biosciences Raises $12.2M

Jun 29, 2017

|

NEW YORK (GenomeWeb) – Swift Biosciences announced today that it has raised $12.2 million through a Series D round of financing.

The round was led by venture capital firm Arboretum Ventures and included existing Swift investors. The company, which develops next-generation sequencing sample prep technologies, said that it intends to use the funding to expand its global commercial channels, as well as enhance its manufacturing and operation capabilities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

To Control the Spread

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

More to Do

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

This Week in PLOS

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

'Follow Me to Maryland'

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.

Featured White Papers

Modular DNA Assembly of PIK3CA Using Acoustic Liquid Transfer in Nanoliter Volumes

Effective Miniaturization of Illumina Nextera XT Library Prep for Multiplexed Whole Genome Sequencing and Microbiome Applications

High-Throughput Microliter-Sized Cell-Free Transcription-Translation Reactions for Synthetic Biology Applications Using the Echo 550 Liquid Handler

Miniaturized 16S rRNA Amplicon Sequencing with the Labcyte Echo 525 Liquid Handler for Metagenomic and Microbiome Studies

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

04

Featured Webinar

Software Tools for NGS-Based Diagnosis of CFTR-Related Diseases in Routine Practice

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Main menu